...
search icon
sldb-img

Solid Biosciences LLC, Common Stock

SLDB

NSQ

$2.765

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$282.88M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.93M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.07
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.45 L
$10.68 H
$2.765

About Solid Biosciences LLC, Common Stock

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSLDBSectorS&P500
1-Week Return-24.11%-1.83%1.17%
1-Month Return3.75%0.87%13.71%
3-Month Return-19.48%-8.31%-6.62%
6-Month Return-52.81%-10.68%-5.57%
1-Year Return-72.98%-5.59%9.24%
3-Year Return-64.17%6.11%41.93%
5-Year Return-92.64%34.94%93.22%
10-Year Return-99.18%82.63%167.77%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue3.33M13.62M8.09M--[{"date":"2020-12-31","value":24.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.43,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue3.92M58.74M2.41M76.56M-[{"date":"2020-12-31","value":5.12,"profit":true},{"date":"2021-12-31","value":76.72,"profit":true},{"date":"2022-12-31","value":3.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(3.92M)(45.12M)5.69M(76.56M)-[{"date":"2020-12-31","value":-68.98,"profit":false},{"date":"2021-12-31","value":-793.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1346.52,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(117.60%)(331.27%)70.25%--[{"date":"2020-12-31","value":-167.4,"profit":false},{"date":"2021-12-31","value":-471.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses86.46M85.87M107.37M104.31M129.73M[{"date":"2020-12-31","value":66.65,"profit":true},{"date":"2021-12-31","value":66.2,"profit":true},{"date":"2022-12-31","value":82.76,"profit":true},{"date":"2023-12-31","value":80.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(88.41M)(72.25M)(106.45M)(104.31M)(129.73M)[{"date":"2020-12-31","value":-8840600000,"profit":false},{"date":"2021-12-31","value":-7225400000,"profit":false},{"date":"2022-12-31","value":-10645200000,"profit":false},{"date":"2023-12-31","value":-10431500000,"profit":false},{"date":"2024-12-31","value":-12972800000,"profit":false}]
Total Non-Operating Income/Expense(1.71M)130.00K23.09M15.32M14.16M[{"date":"2020-12-31","value":-7.42,"profit":false},{"date":"2021-12-31","value":0.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":66.34,"profit":true},{"date":"2024-12-31","value":61.33,"profit":true}]
Pre-Tax Income(88.29M)(72.19M)(85.98M)(96.02M)(124.70M)[{"date":"2020-12-31","value":-8829000000,"profit":false},{"date":"2021-12-31","value":-7218800000,"profit":false},{"date":"2022-12-31","value":-8598100000,"profit":false},{"date":"2023-12-31","value":-9601500000,"profit":false},{"date":"2024-12-31","value":-12469700000,"profit":false}]
Income Taxes1.83M(64.00K)(20.47M)--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-3.5,"profit":false},{"date":"2022-12-31","value":-1119.86,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(90.12M)(72.12M)(65.51M)--[{"date":"2020-12-31","value":-9011800000,"profit":false},{"date":"2021-12-31","value":-7212400000,"profit":false},{"date":"2022-12-31","value":-6551000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(88.29M)(72.19M)(85.98M)(90.83M)(124.70M)[{"date":"2020-12-31","value":-8829000000,"profit":false},{"date":"2021-12-31","value":-7218800000,"profit":false},{"date":"2022-12-31","value":-8598100000,"profit":false},{"date":"2023-12-31","value":-9083000000,"profit":false},{"date":"2024-12-31","value":-12469700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(90.12M)(72.12M)(65.51M)(96.02M)(124.70M)[{"date":"2020-12-31","value":-9011800000,"profit":false},{"date":"2021-12-31","value":-7212400000,"profit":false},{"date":"2022-12-31","value":-6551000000,"profit":false},{"date":"2023-12-31","value":-9601500000,"profit":false},{"date":"2024-12-31","value":-12469700000,"profit":false}]
EPS (Diluted)(24.75)(10.20)(9.99)(4.80)(3.04)[{"date":"2020-12-31","value":-2475,"profit":false},{"date":"2021-12-31","value":-1020,"profit":false},{"date":"2022-12-31","value":-999,"profit":false},{"date":"2023-12-31","value":-480,"profit":false},{"date":"2024-12-31","value":-304,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SLDB
Cash Ratio 4.92
Current Ratio 5.20

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SLDB
ROA (LTM) -45.86%
ROE (LTM) -94.57%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SLDB
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SLDB
Trailing PE NM
Forward PE NM
P/S (TTM) 3.65
P/B 2.43
Price/FCF NM
EV/R 1.16
EV/Ebitda NM

FAQs

What is Solid Biosciences LLC share price today?

Solid Biosciences LLC (SLDB) share price today is $2.765

Can Indians buy Solid Biosciences LLC shares?

Yes, Indians can buy shares of Solid Biosciences LLC (SLDB) on Vested. To buy Solid Biosciences LLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLDB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Solid Biosciences LLC be purchased?

Yes, you can purchase fractional shares of Solid Biosciences LLC (SLDB) via the Vested app. You can start investing in Solid Biosciences LLC (SLDB) with a minimum investment of $1.

How to invest in Solid Biosciences LLC shares from India?

You can invest in shares of Solid Biosciences LLC (SLDB) via Vested in three simple steps:

  • Click on Sign Up or Invest in SLDB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Solid Biosciences LLC shares
What is Solid Biosciences LLC 52-week high and low stock price?

The 52-week high price of Solid Biosciences LLC (SLDB) is $10.68. The 52-week low price of Solid Biosciences LLC (SLDB) is $2.45.

What is Solid Biosciences LLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Solid Biosciences LLC (SLDB) is 2.43

What is the Market Cap of Solid Biosciences LLC?

The market capitalization of Solid Biosciences LLC (SLDB) is $282.88M

What is Solid Biosciences LLC’s stock symbol?

The stock symbol (or ticker) of Solid Biosciences LLC is SLDB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top